Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative treatment for patients with various leukemias. TP-53 controls apoptosis upstream of where BCL-2 and its prosurvival relatives, such as MCL-1, act. Therefore, targeting these prosurvival proteins could trigger apop...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood
Egile Nagusiak: Thijssen, Rachel, Diepstraten, Sarah T., Moujalled, Donia, Chew, Edward, Flensburg, Christoffer, Shi, Melissa X., Dengler, Michael A., Litalien, Veronique, MacRaild, Sarah, Chen, Maoshan, Anstee, Natasha S., Reljić, Boris, Gabriel, Sarah S., Djajawi, Tirta M., Riffkin, Chris D., Aubrey, Brandon J., Chang, Catherine, Tai, Lin, Xu, Zhen, Morley, Thomas, Pomilio, Giovanna, Bruedigam, Claudia, Kallies, Axel, Stroud, David A., Bajel, Ashish, Kluck, Ruth M., Lane, Steven W., Schoumacher, Marie, Banquet, Sébastien, Majewski, Ian J., Strasser, Andreas, Roberts, Andrew W., Huang, David C. S., Brown, Fiona C., Kelly, Gemma L., Wei, Andrew H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2021
Gaiak:
Plenary Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8138548/
https://ncbi.nlm.nih.gov/pubmed/33824975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020010167
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak